CBD Oil for Sleep and Menstrual Cycle Disruption: PMS, PMDD, and the Luteal Phase Sleep Architecture Collapse | PureCraft CBD

By PureCraft Editorial Team | PureCraft CBD | Updated October 2026

Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) produce the only cyclical, monthly sleep disruption in this entire series — a sleep architecture deterioration that is hormonally programmed into a predictable monthly pattern, reliably worsening across the late luteal phase (days twenty-two through twenty-eight of a standard twenty-eight-day cycle), then resolving with menstrual onset, only to repeat. This cyclical predictability is both the most distinguishing feature of menstrual-related sleep disruption and a genuine clinical asset: because the timing is known in advance, interventions can be timed proactively rather than reactively. The mechanisms of late luteal phase sleep disruption are distinct from every other condition in this series. Where the sleep disruption of anxiety involves chronic psychological threat-circuit hyperactivation, where the sleep disruption of Parkinson's involves dopaminergic and REM circuitry degeneration, and where the sleep disruption of Long COVID involves post-viral neuroinflammation, the sleep disruption of the late luteal phase involves a monthly cascade of hormonally-driven neurochemical changes: the sharp decline in progesterone that characterizes the late luteal phase produces a withdrawal of allopregnanolone — the neurosteroid progesterone metabolite that is one of the most potent positive allosteric modulators of GABA-A receptors in the brain — creating a GABA-A tone deficit that destabilizes the inhibitory equilibrium that sleep onset and maintenance require; the concurrent prostaglandin surge (PGE2, PGF2α) from the uterus produces dysmenorrhea pain and systemic inflammatory signaling that activates sleep-disrupting arousal circuits through TRPV1 and COX-2 pathways; late-luteal evening cortisol elevation from HPA dysregulation driven by the progesterone decline impairs the cortisol-melatonin transition that normally enables sleep onset; and the serotonergic deficit that characterizes PMDD — reduced serotonin transporter binding and reduced tryptophan availability across the luteal phase — undermines the sleep-wake architecture that serotonin's raphe nucleus projections stabilize. PMDD, the severe form affecting three to eight percent of menstruating individuals (compared to the forty-seven percent PMS prevalence in milder form), is distinguished by the psychiatric symptom severity — severe depression, anxiety, irritability, and emotional dysregulation in the luteal phase — and the sleep disruption of PMDD is correspondingly more severe, with polysomnographic studies demonstrating measurable reductions in REM density, increased N1 light sleep, and reduced total sleep efficiency. CBD oil does not treat PMS or PMDD, does not regulate the progesterone-allopregnanolone cycle, and does not address the underlying hormonal fluctuation that drives both conditions. The specific mechanisms CBD addresses: GABA-A tone support during allopregnanolone withdrawal; CB2 anti-inflammatory and TRPV1 desensitization for the prostaglandin-driven pain that disrupts sleep onset and produces awakenings; HPA/cortisol modulation for the late-luteal evening cortisol elevation; and 5-HT1A partial agonism for the serotonergic deficit component of PMDD sleep disruption.

The menstrual cycle sleep disruption population is demographically distinct from most other conditions in this series: reproductive-age individuals (typically fifteen to fifty) who are otherwise healthy, are frequently employed or caregiving, and are experiencing a monthly, predictable functional impairment that recurs without end unless treated or until menopause resolves the hormonal cycling. The economic and quality-of-life impact of late-luteal sleep disruption is substantial: studies from multiple countries find PMS-related productivity losses averaging one to two days per cycle, and PMDD produces functional impairment comparable to major depressive disorder during the luteal phase — including significantly impaired sleep that carries into the following day's cognitive performance, emotional regulation, and social functioning. A critical distinction from the perimenopause (P11-203) and menopause (P11-211) posts in this series: those posts address the estrogen withdrawal vasomotor instability and sleep disruption of the menopausal transition, characterized by night sweats, reduced REM, and estrogen/progesterone deficiency. PMS/PMDD sleep disruption is a different condition — occurring in the context of normal, cycling estrogen and progesterone levels, driven by the monthly withdrawal of progesterone and its neurosteroid metabolite rather than by long-term estrogen deficiency — requiring a distinct mechanistic analysis and a different CBD protocol emphasis. The cyclical precision of PMDD/PMS sleep disruption means CBD protocol timing can and should be matched to the hormonal cycle: intensifying during the late luteal phase (days twenty to twenty-eight) and reducing to maintenance levels in the follicular phase (days one to thirteen) when the hormonal drivers of sleep disruption are absent.

How the Luteal Phase and PMDD Disrupt Sleep: Five Distinct Mechanisms

1. Allopregnanolone Withdrawal: The GABA-A Neurosteroid Collapse Unique to This Series

The most biologically distinctive mechanism of menstrual-cycle sleep disruption — and the one with the clearest differentiation from every other condition in this series — is the monthly withdrawal of allopregnanolone, the neurosteroid metabolite of progesterone that is one of the most potent endogenous positive allosteric modulators of GABA-A receptors in the human brain. Understanding this mechanism requires understanding the neurosteroid synthesis pathway: during the luteal phase (days fourteen to twenty-eight of the cycle), progesterone rises substantially as the corpus luteum produces it in preparation for potential implantation. Progesterone is converted in brain tissue, liver, and peripheral tissues by 5α-reductase and 3α-hydroxysteroid dehydrogenase into allopregnanolone (3α,5α-tetrahydroprogesterone), which acts as a powerful positive allosteric modulator of GABA-A receptors — the same receptor class that benzodiazepines and barbiturates act on, but at a distinct binding site. At peak luteal progesterone concentrations, allopregnanolone levels in the brain are sufficient to produce measurable anxiolytic, sedative, and sleep-promoting effects through GABA-A potentiation. This is the neurobiological basis for the subjective experience many menstruating individuals have in the mid-luteal phase (days seventeen to twenty) of feeling slightly more relaxed, sleeper at night, and calmer — the allopregnanolone peak providing a monthly neurosteroid anxiolysis. The late luteal phase (days twenty-two to twenty-eight) reverses this entirely: progesterone and allopregnanolone decline sharply in the absence of implantation, and the GABA-A receptors that had been tonically modulated by allopregnanolone now lose that modulation in a withdrawal pattern that parallels the neurobiological mechanism of benzodiazepine and alcohol withdrawal — reduced GABAergic inhibitory tone producing a neurochemical environment more vulnerable to arousal, anxiety, and sleep disruption. In PMDD, this withdrawal is more severe because PMDD-affected individuals appear to have paradoxical sensitivity to allopregnanolone fluctuation: rather than a smooth descent from allopregnanolone peak to trough, PMDD patients show an exaggerated GABA-A receptor response to the withdrawal that produces heightened anxiety, irritability, and sleep disruption at allopregnanolone concentrations that would be tolerable in PMS individuals. The neuroactive steroid brexanolone (Zulresso, intravenous allopregnanolone) was FDA-approved for postpartum depression in 2019 based precisely on this GABA-A mechanism — demonstrating that restoring allopregnanolone signaling reverses the GABA-A withdrawal syndrome. CBD's intersection with the allopregnanolone withdrawal mechanism is indirect but potentially relevant: while CBD does not directly bind GABA-A receptors in the same way as allopregnanolone, CBD's modulation of the endocannabinoid system — particularly FAAH inhibition elevating anandamide — intersects with GABA-A function through CB1 receptor-mediated inhibition of GABA reuptake in certain hippocampal and prefrontal circuits, supporting inhibitory GABAergic tone. Additionally, CBD's TRPV1 channel modulation at presynaptic terminals can influence GABA release dynamics in the same circuits. This is a supporting mechanism, not a replacement for allopregnanolone's direct GABA-A potentiation — CBD is not a neuroactive steroid and does not substitute for allopregnanolone's mechanism. The framing: CBD provides partial support for the GABAergic inhibitory deficit of allopregnanolone withdrawal through indirect endocannabinoid-GABA circuit interactions, reducing the arousal vulnerability of the late-luteal GABA-A trough state, as one component of a multi-mechanism late-luteal sleep support protocol. This is a mechanism unique to this post — no other condition in this series involves monthly GABA-A neurosteroid withdrawal as the primary sleep-disrupting mechanism.

2. Prostaglandin-Driven Dysmenorrhea Pain: TRPV1, COX-2, and the Pain-Sleep Entry Block

The second distinct mechanism of menstrual sleep disruption is the prostaglandin-driven pain of primary dysmenorrhea — the uterine cramping, lower abdominal pain, and associated back and thigh pain that accompanies menstrual onset and the immediately premenstrual period — which produces a sleep disruption pattern mechanistically identical to the pain-sleep cycle described in the chronic pain post (P11-207) but with the important distinction that this pain is cyclical, predictable, and prostaglandin-specific rather than the generalized or neuropathic pain of chronic conditions. The prostaglandin synthesis pathway: in the late luteal phase and early menstruation, the declining progesterone removes the inhibitory effect on the cyclo-oxygenase (COX) enzymes in the uterine endometrium. COX-1 and COX-2 become highly active, converting arachidonic acid to prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α). PGF2α produces powerful uterine smooth muscle contractions that generate the cramp pain of dysmenorrhea through uterine ischemia (the contracting uterus compresses its own blood supply, producing ischemic pain in addition to the direct myometrial pain from contracting against endometrial tissue). PGE2 sensitizes peripheral nociceptors — including TRPV1 channels — to produce the hyperalgesia that makes the uterus and surrounding tissue abnormally pain-sensitive during menstruation. The systemic prostaglandins (those that enter the bloodstream) produce the systemic dysmenorrhea symptoms: headache, nausea, diarrhea, and the full-body achiness many menstruating individuals experience in the first day or two of menstruation. For sleep: the pain-sleep interaction is bidirectional in exactly the pattern described in the chronic pain post — prostaglandin-driven pain activates the ascending pain pathway, producing hypothalamic arousal that prevents sleep onset and causes early-morning awakenings from dysmenorrhea cramps (particularly between three and six AM, when the diurnal cortisol nadir and lowest pain threshold make pain maximally disruptive). CBD's mechanisms directly target two aspects of the prostaglandin pain pathway: TRPV1 desensitization (reducing the PGE2-sensitized nociceptor activity that produces peripheral pain amplification), and CB2/PPARγ/NF-κB anti-inflammatory signaling that modulates the inflammatory milieu driving COX-2 upregulation and prostaglandin production. The topical cream application is the most directly targeted delivery for dysmenorrhea sleep disruption: the Nano CBD Muscle & Joint Cream applied to the lower abdomen before sleep provides localized TRPV1 desensitization at the site of prostaglandin-sensitized nociception, reducing the peripheral pain signal that drives sleep-onset disruption and nocturnal awakenings. This is the same mechanism identified as most directly targeted in the uremic pruritus section of the CKD post (P11-223) — topical application to the site of TRPV1 activation provides more direct local mechanism engagement than systemic delivery alone. The systemic oil and softgel add CB2 anti-inflammatory coverage for the systemic prostaglandin inflammatory cascade that produces the headache, back pain, and thigh aching of severe dysmenorrhea.

3. Late-Luteal HPA Dysregulation: Evening Cortisol Elevation and the Cortisol-Melatonin Conflict

The third mechanism of late-luteal sleep disruption is HPA axis dysregulation driven by the progesterone decline — an evening cortisol elevation that directly conflicts with the nocturnal melatonin rise that sleep onset requires. The progesterone-cortisol relationship involves progesterone's role as a cortisol-antagonist at the glucocorticoid receptor level: progesterone (and its metabolite allopregnanolone) has mild glucocorticoid antagonist properties that modulate HPA reactivity across the luteal phase. As progesterone declines sharply in the late luteal phase, this cortisol-moderating effect is removed, and the HPA axis becomes more reactive to stressors and maintains elevated evening cortisol rather than following the normal diurnal suppression pattern that should allow cortisol to reach its nadir by midnight. Multiple polysomnographic studies of PMS/PMDD patients have documented elevated late-afternoon and evening cortisol levels in the late luteal phase compared to both the follicular phase and non-PMS controls, with cortisol levels in the eight PM to midnight window sufficient to suppress the melatonin rise that the suprachiasmatic nucleus is signaling the pineal gland to produce. This cortisol-melatonin conflict — elevated cortisol blocking melatonin when melatonin should be rising for sleep — is the mechanism for the characteristically prolonged sleep-onset latency of PMS/PMDD: individuals with late-luteal HPA dysregulation report lying in bed alert and unable to sleep at ten to eleven PM on days twenty-four through twenty-seven of the cycle, experiencing exactly the same wired-but-tired state that the anxiety and burnout posts described — except that here the mechanism is not psychological threat hyperactivation but progesterone-withdrawal-driven HPA disinhibition. The practical consequence: melatonin levels are typically twenty-five to forty percent lower in the late luteal phase than in the follicular phase in PMDD patients, and the cortisol awakening response (CAR) is often blunted — a pattern of elevated pre-sleep evening cortisol followed by a flattened morning cortisol peak, rather than the sharp cortisol rise that healthy HPA function produces. CBD's HPA mechanism — FAAH inhibition elevating anandamide → anandamide-mediated attenuation of CRH output from the paraventricular nucleus (PVN) of the hypothalamus → reduced ACTH → reduced adrenal cortisol → support for the normal nocturnal cortisol nadir — directly addresses the late-luteal evening cortisol elevation. The melatonin gummies component directly addresses the melatonin suppression from this cortisol excess — providing exogenous melatonin at the time when endogenous melatonin production is being blocked by elevated cortisol, helping to establish the melatonin signal that sleep onset requires despite the cortisol elevation. The combination of CBD oil (HPA/cortisol modulation) + melatonin gummies (direct melatonin replacement for cortisol-suppressed endogenous production) is the most targeted approach to the late-luteal cortisol-melatonin conflict.

4. Serotonergic Deficit in PMDD: Raphe Nucleus Dysregulation and Sleep Architecture Destabilization

PMDD — the severe form of premenstrual sleep and mood disruption — has a well-established serotonergic mechanism that distinguishes it from ordinary PMS in both the depth of sleep disruption and the pharmacological response profile. Estrogen and progesterone both influence serotonin system function through multiple pathways: estrogen upregulates serotonin transporter (SERT) expression and tryptophan hydroxylase (the rate-limiting enzyme in serotonin synthesis); progesterone modulates 5-HT2A receptor sensitivity. As both hormones decline in the late luteal phase, serotonergic tone is reduced — but in PMDD patients, this luteal serotonergic decline is more severe and more consequential than in non-PMDD women. Polysomnographic studies of PMDD patients demonstrate measurable sleep architecture changes unique to the luteal phase: reduced REM density (total amount of rapid eye movement during REM periods), increased REM latency (longer time to first REM period), more fragmented REM sleep, increased N1 light sleep at the expense of N3 and REM, and overall reduced sleep efficiency. These REM-specific changes parallel the serotonergic architecture disturbances seen in major depressive disorder (as covered in the depression post, P11-209) — because PMDD's luteal-phase serotonergic deficit mechanistically resembles a monthly episodic depression in its neurochemistry. The raphe nucleus dorsal projections to the forebrain — which are the primary serotonin source for the prefrontal cortex, hippocampus, and limbic circuits governing emotional regulation and sleep-wake boundary stability — are among the circuits most affected by the luteal serotonergic decline in PMDD. The sleep consequence: reduced raphe serotonergic tone → reduced 5-HT2A stimulation of the sleep-regulatory circuits that normally suppress inappropriate REM intrusion and maintain N3 → sleep architecture fragmentation with the REM and N3 changes documented on polysomnography. This is the mechanism basis for SSRIs' effectiveness in PMDD: by blocking serotonin reuptake, SSRIs compensate for the reduced serotonin availability in the late luteal phase, maintaining synaptic serotonergic tone despite the reduced synthesis throughput — and at luteal-phase-only dosing, this compensation operates precisely during the phase when it is needed. CBD's 5-HT1A partial agonism addresses the PMDD serotonergic mechanism from a different point in the circuit: 5-HT1A autoreceptors on raphe nucleus neurons regulate the firing rate of serotonergic neurons, and 5-HT1A partial agonism can both sensitize postsynaptic 5-HT1A receptors in the hippocampus and prefrontal cortex (producing anxiolytic and mood-stabilizing effects) and modulate raphe autoreceptor function. This is the same mechanism operative in the anxiety and depression posts, applied to the PMDD-specific serotonergic context. For PMDD patients on SSRI luteal-phase dosing: CBD adds 5-HT1A modulation that is mechanistically complementary to SSRI reuptake inhibition — different targets in the serotonergic system, addressing the PMDD serotonergic deficit from both the synaptic concentration side (SSRI) and the receptor sensitivity side (CBD 5-HT1A).

5. Cyclical Anxiety, Emotional Dysregulation, and Pre-Sleep Cognitive Hyperarousal

The fifth mechanism of PMDD/PMS sleep disruption integrates the psychological and somatic components that the first four mechanisms generate: the allopregnanolone withdrawal-driven anxiety, the serotonergic deficit-driven emotional dysregulation, the progesterone-withdrawal HPA disinhibition driving mood lability, and the accumulated fatigue and frustration of the predictable monthly deterioration combine to produce a late-luteal psychological state that is highly conducive to the pre-sleep cognitive hyperarousal that prevents sleep initiation. This is not a separate neurobiological mechanism from the four above — it is the behavioral and psychological expression of those mechanisms in the pre-sleep period. The individual lies in bed aware of the characteristic PMDD cluster: racing thoughts, excessive worry, emotional sensitivity, irritability at small stimuli, a sense of dread about the coming day, and the particularly cruel awareness that these feelings are temporary but currently overwhelming. This pre-sleep cognitive hyperarousal pattern is identical in its sleep-disruption mechanism to the anxiety post (P11-210) — the prefrontal default mode network activating rumination, the amygdala maintaining threat-signal arousal, the insular cortex maintaining body-focused hypervigilance (bloating, breast tenderness, cramp anticipation) — with the important distinction that the underlying driver is the hormonal cascade of the late luteal phase rather than trait anxiety. This distinction matters for both the framing and the intervention: PMDD pre-sleep hyperarousal is not primarily a psychological problem requiring cognitive-behavioral intervention, though CBT-I components are useful adjuncts. It is a neurobiologically-generated psychological state that will resolve with menstrual onset regardless of cognitive or behavioral intervention, and the most effective approach targets the underlying biological drivers (allopregnanolone withdrawal, serotonergic deficit, HPA disinhibition) rather than treating the hyperarousal as primary. CBD's most immediate mechanism for the pre-sleep cognitive hyperarousal of PMDD is 5-HT1A partial agonism — reducing the amygdala hyperreactivity and the prefrontal cortex rumination circuit activation that the serotonergic deficit and allopregnanolone withdrawal produce. The anxiolytic component is the fastest-acting CBD mechanism (one to two weeks of consistent use) and produces the most immediately noticeable sleep-onset improvement in the first cycles of CBD use. The HPA/FAAH mechanism reduces the evening cortisol drive that is amplifying the psychological arousal through the wired-but-tired state. In combination, these two mechanisms address the psychological expression of the late-luteal neurobiological state that manifests as pre-sleep cognitive hyperarousal — attacking it at the serotonergic and cortisol levels that generate it, rather than attempting to cognitively override a physiologically-driven arousal state.

Menstrual Cycle Phase and CBD Protocol Relevance

Population Profiles

CBD Oil Protocol for Menstrual Cycle Sleep Disruption

PureCraft Products for PMS/PMDD Sleep Disruption

Late-Luteal ANS and Serotonergic Support: Oil for HPA, 5-HT1A, and GABA-Adjacent Mechanisms

The Nano CBD Broad Spectrum Oil is the primary vehicle for the 5-HT1A partial agonism (addressing PMDD serotonergic deficit and pre-sleep cognitive hyperarousal), FAAH/anandamide HPA modulation (addressing late-luteal evening cortisol elevation), and endocannabinoid-GABA circuit support (providing partial supplementary GABAergic support during allopregnanolone withdrawal). Begin the late-luteal dose increase two to three days before the individual's typical PMS/PMDD symptom onset, with the oil taken forty-five minutes before sleep. The nanoemulsion format ensures consistent bioavailability during the hormonal fluctuation of the late luteal phase — unlike standard CBD oil, whose GI absorption can be affected by the GI motility changes (bloating, constipation-diarrhea cycling) that some individuals experience in the PMS window, the sublingual nanoemulsion bypasses GI absorption variability.

Melatonin Replacement and N3 Architecture: CBN/Melatonin Gummies for Late-Luteal Phase

The CBD+CBN+D9+Melatonin Gummies address the two most critical sleep architecture deficits of the late-luteal phase: the cortisol-suppressed melatonin production (direct melatonin supplementation at the time the endogenous evening melatonin peak is being blocked by elevated late-luteal cortisol) and the N3 slow-wave sleep deficit from allopregnanolone withdrawal and serotonergic impairment (CBN's N3 promotion in the context of reduced GABAergic inhibitory tone). Taken sixty to ninety minutes before sleep onset — slightly earlier than the oil, to allow the melatonin to begin establishing the circadian signal before the sleep-onset window. The melatonin component is particularly important in the late-luteal phase, where the cortisol-melatonin conflict means natural melatonin production is being actively suppressed by elevated cortisol at exactly the time sleep onset requires it.

Lower Abdominal Pain Management: Cream for Dysmenorrhea TRPV1 Desensitization

The Nano CBD Muscle & Joint Cream is uniquely positioned for menstrual-related sleep disruption in this series because dysmenorrhea pain is the most site-specific sleep disruptor in any condition covered here — the pain originates in the uterus and radiates to the lower abdomen, lower back, and thighs in a predictable anatomical pattern. Applied to the lower abdomen (overlying the uterus) and lower back before sleep during the dysmenorrhea window (days twenty-six through twenty-eight and menstrual days one and two), the cream provides localized TRPV1 desensitization at the prostaglandin-sensitized nociceptor sites — directly reducing the peripheral pain signal that drives sleep-onset block and nocturnal awakening from dysmenorrhea. The cream does not address the uterine smooth muscle contraction mechanism of dysmenorrhea (no CBD mechanism for smooth muscle relaxation at therapeutic topical doses), but it significantly reduces the nociceptor hyperalgesia that makes the contraction pain disproportionately severe. For individuals who find NSAID use before bed reduces GI sleep disruption from prostaglandin systemic symptoms (nausea, cramping): the cream provides a topical, GI-neutral complement to NSAID's systemic COX inhibition.

Early Morning Cramping Coverage: Softgels for the Three-to-Five AM Awakening Window

The Nano CBD Water-Soluble Broad Spectrum Softgels provide the overnight extension of CB2 anti-inflammatory and TRPV1 modulation that addresses the characteristic three-to-five AM dysmenorrhea awakening — when circadian cortisol is at its nadir, pain threshold is lowest, and prostaglandin-driven uterine contractions produce the most disruptive pain of the menstrual cycle. The softgel taken at sleep onset, combined with the oil taken forty-five minutes before sleep, provides layered coverage: the oil's faster-acting sublingual mechanisms through the first half of the night, and the softgel's sustained-release coverage through the early morning window when the pain-awakening risk is highest. For PMDD patients whose late-luteal anxiety extends into early-morning awakening with racing thoughts and inability to return to sleep (a pattern distinct from pain awakening), the softgel's overnight ANS and 5-HT1A coverage also limits the early-morning hyperarousal that the late-luteal neurochemical environment produces.

Frequently Asked Questions About CBD Oil for PMS and PMDD Sleep Disruption

Related Articles

• → CBD Oil for Sleep and Perimenopause: Estrogen Fluctuation, Night Sweats, and the Perimenopausal Sleep Architecture Shift
• → CBD Oil for Sleep and Menopause: Estrogen Deficiency, Vasomotor Instability, and REM Architecture Disruption
• → CBD Oil for Sleep and Anxiety: Pre-Sleep Cognitive Hyperarousal, Evening Cortisol, and ANS Sympathetic Lock
• → CBD Oil for Sleep and Chronic Pain: The Bidirectional Pain-Sleep Cycle and TRPV1 Desensitization
• → Nano CBD Oil: Why Nanoemulsion Bioavailability Changes Everything About CBD Dosing

References

1. Blessing EM, et al. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825–836. PMID: 26341731
2. Shannon S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18–041. PMID: 30624194
3. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2016;4(1):245–259. PMID: 28861491
4. Crippa JA, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder. J Psychopharmacol. 2011;25(1):121–130. PMID: 20829306
5. Corroon J, Phillips JA. A Cross-Sectional Study of Cannabidiol Users. Cannabis Cannabinoid Res. 2018;3(1):152–161. PMID: 30014049
6. Capano A, et al. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients. Postgrad Med. 2020;132(1):56–61. PMID: 31711352